Clinical Trial Update: Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial reports tolerability, pharmacokinetics, and Dopamine β-hydroxylase inhibition of the drug candidate BIA 5-453 in hypertension and heart f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Hypertension

Drugs mentioned

• BIA 5-453

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Hypertension, Chronic Heart Failure | Phase 1 | Status: COMPLETED